Researchers at University of Nigeria Zero in on Kidney Disease (Cost analysis of the management of end-stage renal disease patients in Abuja, Nigeria): Kidney Diseases and Conditions – Kidney Disease

2023 DEC 26 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Researchers detail new data in kidney disease. According to news originating from the University of Nigeria by NewsRx correspondents, research stated, “Although the treatment for end-stage renal disease (ESRD) under Nigeria’s National Health Insurance Authority is haemodialysis (HD), the cost of managing ESRD is understudied in Nigeria. Therefore, this study estimated the provider and patient direct costs of haemodialysis and managing ESRD in Abuja, Nigeria.”

Our news correspondents obtained a quote from the research from University of Nigeria: “The study was a cross-sectional survey from both healthcare provider and consumer perspectives. We collected data from public and private tertiary hospitals (n = 6) and ESRD patients (n = 230) receiving haemodialysis in the selected hospitals. We estimated the direct providers’ costs using fixed and variable costs. Patients’ direct costs included drugs, laboratory services, transportation, feeding, and comorbidities. Additionally, data on the sociodemographic and clinical characteristics of patients were collected. The costs were summarized in descriptive statistics using means and percentages. A generalized linear model (gamma with log link) was used to predict the patient characteristics associated with patients’ cost of haemodialysis. The mean direct cost of haemodialysis was $152.20 per session (providers: $123.69; and patients: $28.51) and $23,742.96 annually (providers: $19,295.64; and patients: $4,447.32). Additionally, patients spent an average of $2,968.23 managing comorbidities. The drivers of providers’ haemodialysis costs were personnel and supplies. Residing in other towns (HD:b = 0.55, r = 0.001; ESRD:b = 0.59, r = 0.004), lacking health insurance (HD:b = 0.24, r = 0.038), attending private health facility (HD:b = 0.46, r < 0.001; ESRD: b = 0.75, r < 0.001), and greater than six haemodialysis sessions per month (HD:b = 0.79, r < 0.001; ESRD: b = 0.99, r < 0.001) significantly increased the patient’s out-of-pocket spending on haemodialysis and ESRD.”

According to the news reporters, the research concluded: “The costs of haemodialysis and managing ESRD patients are high. Providing public subsidies for dialysis and expanding social health insurance coverage for ESRD patients might reduce the costs.”

For more information on this research see: Cost analysis of the management of end-stage renal disease patients in Abuja, Nigeria. Cost Effectiveness and Resource Allocation, 2023,21(1):1-10. (Cost Effectiveness and Resource Allocation - http://www.resource-allocation.com/). The publisher for Cost Effectiveness and Resource Allocation is BMC.

A free version of this journal article is available at https://doi.org/10.1186/s12962-023-00502-3.

Our news editors report that more information may be obtained by contacting Yakubu Adole Agada-Amade, Department of Health Administration and Management, University of Nigeria. Additional authors for this research include Daniel Chukwuemeka Ogbuabor, Ejemai Eboreime, Obinna Emmanuel Onwujekwe.

(Our reports deliver fact-based news of research and discoveries from around the world.)